Dr. Hadi Hassannia, Mazandaran University of Medical Sciences, Iran
Dr. Hadi Hassannia is a prominent researcher at the Amol Faculty of Paramedical Sciences and the Immunogenetic Research Center of Mazandaran University of Medical Sciences in Sari, Iran. His research focuses on cancer immunotherapy and vaccine development, with significant publications on tumor inhibition and insulin-producing cells from stem cells. Dr. Hassannia possesses advanced technical skills in genetic engineering, antibody production, and molecular techniques. His experience as a lab technician in diagnostic laboratories has enriched his practical knowledge in various fields, including hematology and immunology. He is committed to advancing cancer research and therapeutic approaches. š§¬š¬š
Publication Profile
Google Scholar
Work Experience
Dr. Hassannia has a robust work history, having served as a lab technician in various diagnostic laboratories in governmental hospitals from 2009 to 2017. His practical experience in clinical settings enriches his research with a real-world perspective, further bridging the gap between laboratory findings and clinical applications.
Technical Skills
Dr. Hassannia possesses a diverse skill set that enhances his research capabilities:
Genetic Engineering: He has significant experience in genetic engineering, including protein manipulation and monoclonal antibody production.
Immunological Techniques: Proficient in advanced immunological techniques such as flow cytometry, Western blotting, and ELISA, he is well-equipped to conduct comprehensive immunological research.
Molecular Techniques: His expertise extends to molecular biology techniques like PCR and gene transfection, which are essential for cancer research and therapeutic development.
Laboratory Animal Handling: His experience with laboratory animals allows him to perform complex experiments, including tumor induction, vital for his research in cancer models.
Research Interests
Cancer Vaccine Development: His work in developing cancer vaccines contributes to the growing field of immunotherapy, which seeks to harness the bodyās immune system to combat cancer.
Immunotherapy: He is engaged in research focused on immunotherapy approaches for cancer treatment, highlighting his commitment to improving patient outcomes.
Cancer-Related Inflammation: Understanding the role of inflammation in cancer progression is a critical area of his research, as it can lead to new therapeutic targets.
Tumor Metastasis: His interest in tumor metastasis is vital for understanding how cancer spreads and devising strategies to prevent it.
Conclusion
Dr. Hadi Hassannia’s extensive research experience, impressive publication record, and technical skills make him an exceptional candidate for the Best Researcher Award. His contributions to cancer research, particularly in immunotherapy and vaccine development, demonstrate his potential to impact the field significantly and advance medical science.
Publication Top Notes
- CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice – Cited by: 165, Year: 2017 š§¬
- Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles – Cited by: 85, Year: 2016 š
- Blockage of immune checkpoint molecules increases Tācell priming potential of dendritic cell vaccine – Cited by: 76, Year: 2020 š
- Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway – Cited by: 72, Year: 2019 š
- Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine – Cited by: 67, Year: 2020 āļø
- Antiāangiogenic effects of CD73āspecific siRNAāloaded nanoparticles in breast cancerābearing mice – Cited by: 67, Year: 2018 š±
- Antiāinflammatory and antiātumor effects of Ī±-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model – Cited by: 59, Year: 2018 š¼
- Myeloid-derived suppressor cells in B cell malignancies – Cited by: 59, Year: 2015 š¦
- FOXP3 and TGF-Ī² gene polymorphisms in allergic rhinitis – Cited by: 54, Year: 2011 šæ
- Improved osteogenic differentiation of human induced pluripotent stem cells cultured on polyvinylidene fluoride/collagen/plateletārich plasma composite nanofibers – Cited by: 53, Year: 2020 š§Ŗ